Guardant Shares Rise After FDA Approves Colon Cancer Blood Test

Guardant Health Inc. shares rose after US regulators approved the company’s blood test for colorectal cancer as a primary screening tool at a time when the disease is rising at a worrying rate in younger Americans. The US Food and Drug Administration cleared the test, known as Shield, in adults 45 and older who are at average risk for the disease, the Palo Alto, Calif.-based company said in a statement. It’s the first blood test to be approved as a first-line screening option for colorectal cancer, the second-leading cause of...